drugset

drugset / Trial / NCT02825576

Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine

NCT02825576 ↗

Phase 4 Terminated 30 enrolled Northern Sydney Anaesthesia Research Institute Merck Sharp & Dohme LLC · collab Northern Sydney and Central Coast Area Health Service · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to determine if the use of sugammadex (compared with neostigmine) reduces the rate of postoperative pulmonary complications (PPCs).

Timeline

Start: 2018-12-03
Primary completion: 2020-04-01
Completion: 2021-01-01

Publications

Results Olesnicky B, Doane M, Farrell C, Knoblanche G, Delaney A. Prevention of Postoperative Events following Reversal with Sugammadex or Neostigmine (the P-PERSoN Trial): Pilot Data Following Early Termination of a Prospective, Blinded, Randomised Trial. Anesthesiol Res Pract. 2022 Jul 8;2022:4659795. doi: 10.1155/2022/4659795. eCollection 2022.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Neostigmine	Other / unclassified	50 ug/kg	Intravenous
Comparator	Sugammadex	Other / unclassified	2 mg/kg	Intravenous
Comparator	Glycopyrrolate	Small molecule	10 ug/kg	Intravenous

Indications

No indication recorded.